Year Published
- 2008 (0)
- 2009 (0)
- 2010 (0)
- 2011 (0)
- (-) Remove 2012 filter 2012
- 2013 (0)
- 2014 (0)
- (-) Remove 2015 filter 2015
- 2016 (3) Apply 2016 filter
- 2017 (5) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (1) Apply 2021 filter
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (0)
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove Poverty filter Poverty
- (-) Remove Research & Development filter Research & Development
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove Global filter Global
- (-) Remove 2015 filter 2015
- (-) Remove 2012 filter 2012
- (-) Remove 2018 filter 2018
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The literature on poverty’s causes and cures in developing countries posits a variety of contributing factors. Most researchers acknowledge that a sustained exit from poverty is complex and no single causal pathway from poverty to non-poverty exists. In this review, we present a summary framework for categorizing the various theorized pathways out of poverty, and evaluate the empirical evidence for which interventions and resulting outcomes are most frequently and most strongly associated with poverty alleviation. We conducted a literature review on pathways out of poverty for low-income households in developing countries and identified and categorized general strategies and outcomes demonstrated to be empirically associated with poverty alleviation. We organized the general strategies into four asset groups that could be targeted to alleviate poverty: human, natural, built / financial, and social / political. Much of the literature presents positive results on poverty alleviation, but it is difficult to compare across studies because many of the studies were conducted in different countries and at different scales, and use a variety of outcome measures.